source
- FDA issues warning letters to manufacturers over CGMP and GLP violationsThe U.S. Food and Drug Administration has sent warning letters to multiple drug manufacturers for failing to meet current good manufacturing practice requirements. The agency highlighted problems e…
- Osivax’s flu vaccine OVX836 misses primary efficacy goal in phase 2b trialOsivax announced that its influenza A vaccine candidate OVX836 failed to meet the primary efficacy endpoint in a phase 2b trial involving 2,850 healthy adults in Europe. The trial showed a vaccine…